Meta-Analysis of EGFR Kinase Inhibitors: Not Always Greater Than the Sum of Its Parts

被引：2

作者：

Cardarella, Stephanie ^{[1
,2
,3
]}

Johnson, Bruce E. ^{[1
,2
,3
]}

机构：

[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA

[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2013年 / 105卷 / 09期

关键词：

CELL LUNG-CANCER; 1ST-LINE TREATMENT; CARBOPLATIN-PACLITAXEL; OPEN-LABEL; GEFITINIB; CHEMOTHERAPY; MUTATIONS; ERLOTINIB; MULTICENTER; GEMCITABINE;

D O I：

10.1093/jnci/djt085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：589 / 590

页数：2

共 19 条

[1] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis [J].

Bria, E. ;

Milella, M. ;

Cuppone, F. ;

Novello, S. ;

Ceribelli, A. ;

Vaccaro, V. ;

Sperduti, I. ;

Gelibter, A. ;

Scagliotti, G. V. ;

Cognetti, F. ;

Giannarelli, D. .

ANNALS OF ONCOLOGY, 2011, 22 (10) :2277-2285

[2] Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial [J].

Douillard, Jean-Yves ;

Shepherd, Frances A. ;

Hirsh, Vera ;

Mok, Tony ;

Socinski, Mark A. ;

Gervais, Radj ;

Liao, Mei-Lin ;

Bischoff, Helge ;

Reck, Martin ;

Sellers, Mark V. ;

Watkins, Claire L. ;

Speake, Georgina ;

Armour, Alison A. ;

Kim, Edward S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) :744-752

[3] Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials [J].

Gao, Guanghui ;

Ren, Shengxiang ;

Li, Aiwu ;

Xu, Jianfang ;

Xu, Qinghua ;

Su, Chunxia ;

Guo, Jian ;

Deng, Qinfang ;

Zhou, Caicun .

INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) :E822-E829

[4] TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR. [J].

Garassino, Marina Chiara ;

Martelli, Olga ;

Bettini, Anna ;

Floriani, Irene ;

Copreni, Elena ;

Lauricella, Calogero ;

Ganzinelli, Monica ;

Marabese, Mirko ;

Broggini, Massimo ;

Veronese, Silvio ;

Gherardi, Giorgio ;

Longo, Flavia ;

Fabbri, Maria Agnese ;

Tomirotti, Maurizio ;

Alabiso, Oscar ;

Sarobba, Maria Giuseppa ;

Labianca, Roberto ;

Marsoni, Silvia ;

Farina, Gabriella ;

Scanni, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[5] First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial [J].

Gridelli, Cesare ;

Ciardiello, Fortunato ;

Gallo, Ciro ;

Feld, Ronald ;

Butts, Charles ;

Gebbia, Vittorio ;

Maione, Paolo ;

Morgillo, Floriana ;

Genestreti, Giovenzio ;

Favaretto, Adolfo ;

Leighl, Natasha ;

Wierzbicki, Rafal ;

Cinieri, Saverio ;

Alam, Yasmin ;

Siena, Salvatore ;

Tortora, Giampaolo ;

Felletti, Raffaella ;

Riccardi, Ferdinando ;

Mancuso, Gianfranco ;

Rossi, Antonio ;

Cantile, Flavia ;

Tsao, Ming-Sound ;

Saieg, Mauro ;

Santos, Gilda da Cunha ;

Piccirillo, Maria Carmela ;

Di Maio, Massimo ;

Morabito, Alessandro ;

Perrone, Francesco .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) :3002-3011

[6] First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung [J].

Han, Ji-Youn ;

Park, Keunchil ;

Kim, Sang-We ;

Lee, Dae Ho ;

Kim, Hyae Young ;

Kim, Heung Tae ;

Ahn, Myung Ju ;

Yun, Tak ;

Ahn, Jin Seok ;

Suh, Cheolwon ;

Lee, Jung-Shin ;

Yoon, Sung Jin ;

Han, Jong Hee ;

Lee, Jae Won ;

Jo, Sook Jung ;

Lee, Jin Soo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1122-1128

[7] EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma [J].

He, Mai ;

Capelletti, Marzia ;

Nafa, Khedoudja ;

Yun, Cai-Hong ;

Arcila, Maria E. ;

Miller, Vincent A. ;

Ginsberg, Michelle S. ;

Zhao, Binsheng ;

Kris, Mark G. ;

Eck, Michael J. ;

Jaenne, Pasi A. ;

Ladanyi, Marc ;

Oxnard, Geoffrey R. .

CLINICAL CANCER RESEARCH, 2012, 18 (06) :1790-1797

[8] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J].

Inoue, A. ;

Kobayashi, K. ;

Maemondo, M. ;

Sugawara, S. ;

Oizumi, S. ;

Isobe, H. ;

Gemma, A. ;

Harada, M. ;

Yoshizawa, H. ;

Kinoshita, I. ;

Fujita, Y. ;

Okinaga, S. ;

Hirano, H. ;

Yoshimori, K. ;

Harada, T. ;

Saijo, Y. ;

Hagiwara, K. ;

Morita, S. ;

Nukiwa, T. .

ANNALS OF ONCOLOGY, 2013, 24 (01) :54-59

[9] American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy [J].

Keedy, Vicki Leigh ;

Temin, Sarah ;

Somerfield, Mark R. ;

Beasley, Mary Beth ;

Johnson, David H. ;

McShane, Lisa M. ;

Milton, Daniel T. ;

Strawn, John R. ;

Wakelee, Heather A. ;

Giaccone, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :2121-2127

[10] Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial [J].

Kim, Edward S. ;

Hirsh, Vera ;

Mok, Tony ;

Socinski, Mark A. ;

Gervais, Radj ;

Wu, Yi-Long ;

Li, Long-Yun ;

Watkins, Claire L. ;

Sellers, Mark V. ;

Lowe, Elizabeth S. ;

Sun, Yan ;

Liao, Mei-Lin ;

Osterlind, Kell ;

Reck, Martin ;

Armour, Alison A. ;

Shepherd, Frances A. ;

Lippman, Scott M. ;

Douillard, Jean-Yves .

LANCET, 2008, 372 (9652) :1809-1818

← 1 2 →